Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Renal Cell 73Neoplasm Metastasis 30Kidney Neoplasms 26Neoplasms 19Breast Neoplasms 14Prostatic Neoplasms 12Urinary Bladder Neoplasms 10Melanoma 9Gastrointestinal Stromal Tumors 9Brain Neoplasms 9Glioblastoma 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 7Liver Neoplasms 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Esophageal Neoplasms 5Colorectal Neoplasms 5Thyroid Neoplasms 4Solid Tumors 4Osteosarcoma 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Adenocarcinoma 4Uveal Melanoma 3Thymoma 3Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Cyclophosphamide 9Temozolomide 7Radiotherapy 6Magnetic Resonance Spectroscopy 5Filgrastim 5Cisplatin 5Carboplatin 5antineoplaston AS 2-1 4antineoplaston A10 4Etoposide 4sargramostim 3Vincristine 3Thiotepa 3Melphalan 3Automobiles 3fludarabine 2aldesleukin 2Thalidomide 2Surveys and Questionnaires 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Eflornithine 2Donepezil 2Carmustine 2Biopsy 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2trifluridine tipiracil drug combination 1trametinib 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroectodermal Tumors, Primitive × Sunitinib × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡